Three new medicines for use by NHS Scotland

The Scottish Medicines Consortium (SMC) has approved the use of three new medicines for use by NHS Scotland, including a new treatment for breast cancer.

The palbociclib drug, taken in tablet form, can increase the amount of time sufferers have before breast cancer progresses, and as an oral treatment it is easier to administer. Breast Cancer Care Scotland said the decision would provide ‘equal access’ for patients in Scotland for the treatment, which is already available in England.

The SMC has also approved the use of aviptadil for erectile dysfunction and eliglustat for the treatment of Gaucher disease, a rare inherited disorder that can trigger excessive fatigue, spontaneous bleeding and bone pain.

Dr Alan MacDonald, chairman of the SMC, said: “I am pleased the committee has been able to accept these three medicines for use by NHSScotland. From the testimonies we heard from patient groups and clinicians through our PACE meeting, we know eliglustat will be welcomed by patients and their carers, particularly as it reduces the burden of current treatment and may improve quality of life.

“Palbociclib offers patients with advanced breast cancer the potential for valuable additional time with their families and may delay the need for chemotherapy treatment for some patients. Aviptadil/phenotolamine is a useful addition for the treatment of erectile dysfunction, particularly as it may have fewer side effects than some other therapies.”

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho